Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $51,468.30 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,490 shares of the business’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $51,468.30. Following the completion of the transaction, the chief financial officer now directly owns 54,479 shares of the company’s stock, valued at approximately $1,126,080.93. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Thursday, August 1st, Houte Hans Van sold 3,477 shares of Nurix Therapeutics stock. The stock was sold at an average price of $21.45, for a total value of $74,581.65.
• On Thursday, May 2nd, Houte Hans Van sold 3,499 shares of Nurix Therapeutics stock. The stock was sold at an average price of $12.83, for a total value of $44,892.17.

Nurix Therapeutics Stock Down 1.9 %

Shares of NRIX opened at $21.47 on Friday. Nurix Therapeutics, Inc. has a 1 year low of $4.22 and a 1 year high of $24.38. The business’s 50 day simple moving average is $19.21 and its 200-day simple moving average is $14.76.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.08). The firm had revenue of $12.09 million for the quarter, compared to analysts’ expectations of $19.35 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. Research analysts predict that Nurix Therapeutics, Inc. will post -2.78 EPS for the current fiscal year.

Institutional Trading of Nurix Therapeutics

Several hedge funds have recently modified their holdings of the company. Redmile Group LLC raised its holdings in shares of Nurix Therapeutics by 37.7% during the 1st quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock worth $65,900,000 after acquiring an additional 1,226,497 shares in the last quarter. Vanguard Group Inc. increased its position in Nurix Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 2,714,845 shares of the company’s stock valued at $21,339,000 after acquiring an additional 22,804 shares during the last quarter. Affinity Asset Advisors LLC raised its stake in shares of Nurix Therapeutics by 17.4% in the first quarter. Affinity Asset Advisors LLC now owns 810,253 shares of the company’s stock valued at $11,911,000 after acquiring an additional 120,141 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Nurix Therapeutics by 9.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 622,297 shares of the company’s stock worth $6,422,000 after acquiring an additional 53,721 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Nurix Therapeutics by 73.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 434,413 shares of the company’s stock worth $6,386,000 after purchasing an additional 184,086 shares during the period.

Analysts Set New Price Targets

A number of brokerages have weighed in on NRIX. Stifel Nicolaus reissued a “buy” rating and issued a $27.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, May 15th. JPMorgan Chase & Co. boosted their price target on Nurix Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. HC Wainwright boosted their price target on Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, June 18th. Stephens began coverage on Nurix Therapeutics in a research note on Tuesday, May 14th. They set an “overweight” rating and a $20.00 price target for the company. Finally, Piper Sandler restated an “overweight” rating and set a $35.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $26.67.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.